Table 1.

Evaluation of published reports on drug-induced thrombocytopenia.

Adapted from www.ouhsc.edu/platelets
*Criteria for non-evaluable data: insufficient patient data in the report; platelet count not <100,000/μL; cytotoxic drug, marrow suppression; non-therapeutic agent or used in non-therapeutic manner; drug-induced disease in addition to thrombocytopenia; patient age <16 years. 
Criteria for evaluation of individual patient data 
  1. Drug administration preceded thrombocytopenia; recovery from thrombocytopenia complete and sustained after drug discontinued

  2. Other drugs administered prior to thrombocytopenia were continued or reintroduced after discontinuation of the suspected drug

  3. Other etiologies of thrombocytopenia excluded

  4. Re-exposure to the drug resulted in recurrent thrombocytopenia

 
Levels of evidence
  1. Definite: all 4 criteria met

  2. Probable: Criteria 1–3 met

  3. Possible: Criterion 1 met

  4. Unlikely: Criterion 1 not met

  5. Data not evaluable*

 
Criteria for evaluation of group data 
Levels of evidence
  1. Definite: randomized controlled clinical trial demonstrating significantly greater frequency of thrombocytopenia in the drug administration group

  2. Probable: non-randomized clinical trial demonstrating greater frequency of thrombocytopenia in the drug administration group

  3. Possible: case series without controls reporting thrombocytopenia associated with drug administration

  4. Data not evaluable*

 
Adapted from www.ouhsc.edu/platelets
*Criteria for non-evaluable data: insufficient patient data in the report; platelet count not <100,000/μL; cytotoxic drug, marrow suppression; non-therapeutic agent or used in non-therapeutic manner; drug-induced disease in addition to thrombocytopenia; patient age <16 years. 
Criteria for evaluation of individual patient data 
  1. Drug administration preceded thrombocytopenia; recovery from thrombocytopenia complete and sustained after drug discontinued

  2. Other drugs administered prior to thrombocytopenia were continued or reintroduced after discontinuation of the suspected drug

  3. Other etiologies of thrombocytopenia excluded

  4. Re-exposure to the drug resulted in recurrent thrombocytopenia

 
Levels of evidence
  1. Definite: all 4 criteria met

  2. Probable: Criteria 1–3 met

  3. Possible: Criterion 1 met

  4. Unlikely: Criterion 1 not met

  5. Data not evaluable*

 
Criteria for evaluation of group data 
Levels of evidence
  1. Definite: randomized controlled clinical trial demonstrating significantly greater frequency of thrombocytopenia in the drug administration group

  2. Probable: non-randomized clinical trial demonstrating greater frequency of thrombocytopenia in the drug administration group

  3. Possible: case series without controls reporting thrombocytopenia associated with drug administration

  4. Data not evaluable*

 

or Create an Account

Close Modal
Close Modal